GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Cynata Therapeutics Ltd (STU:51S) » Definitions » EV-to-FCF

Cynata Therapeutics (STU:51S) EV-to-FCF : -3.16 (As of Dec. 11, 2024)


View and export this data going back to 2023. Start your Free Trial

What is Cynata Therapeutics EV-to-FCF?

EV-to-FCF is calculated as enterprise value divided by its free cash flow. As of today, Cynata Therapeutics's Enterprise Value is €19.37 Mil. Cynata Therapeutics's Free Cash Flow for the trailing twelve months (TTM) ended in Dec. 2023 was €-6.13 Mil. Therefore, Cynata Therapeutics's EV-to-FCF for today is -3.16.

The historical rank and industry rank for Cynata Therapeutics's EV-to-FCF or its related term are showing as below:

STU:51S' s EV-to-FCF Range Over the Past 10 Years
Min: -54.94   Med: -16.09   Max: -2.24
Current: -3.46

During the past 13 years, the highest EV-to-FCF of Cynata Therapeutics was -2.24. The lowest was -54.94. And the median was -16.09.

STU:51S's EV-to-FCF is ranked worse than
100% of 386 companies
in the Biotechnology industry
Industry Median: 8.605 vs STU:51S: -3.46

EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.

As of today (2024-12-11), Cynata Therapeutics's stock price is €0.12. Cynata Therapeutics's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 was €-0.018. Therefore, Cynata Therapeutics's PE Ratio (TTM) for today is At Loss.


Cynata Therapeutics EV-to-FCF Historical Data

The historical data trend for Cynata Therapeutics's EV-to-FCF can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Cynata Therapeutics EV-to-FCF Chart

Cynata Therapeutics Annual Data
Trend Jun15 Jun16 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23 Jun24
EV-to-FCF
Get a 7-Day Free Trial Premium Member Only Premium Member Only -17.06 -8.84 -8.42 -0.44 -4.70

Cynata Therapeutics Semi-Annual Data
Dec14 Jun15 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24
EV-to-FCF Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -8.42 - -0.44 - -4.70

Competitive Comparison of Cynata Therapeutics's EV-to-FCF

For the Biotechnology subindustry, Cynata Therapeutics's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Cynata Therapeutics's EV-to-FCF Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Cynata Therapeutics's EV-to-FCF distribution charts can be found below:

* The bar in red indicates where Cynata Therapeutics's EV-to-FCF falls into.



Cynata Therapeutics EV-to-FCF Calculation

Cynata Therapeutics's EV-to-FCF for today is calculated as:

EV-to-FCF=Enterprise Value (Today)/Free Cash Flow (TTM)
=19.372/-6.13
=-3.16

Cynata Therapeutics's current Enterprise Value is €19.37 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Cynata Therapeutics's Free Cash Flow for the trailing twelve months (TTM) ended in Dec. 2023 was €-6.13 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Cynata Therapeutics  (STU:51S) EV-to-FCF Explanation

EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.

Cynata Therapeutics's PE Ratio (TTM) for today is calculated as:

PE Ratio (TTM)=Share Price (Today)/Earnings per Share (Diluted) (TTM)
=0.12/-0.018
=At Loss

Cynata Therapeutics's share price for today is €0.12.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Cynata Therapeutics's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 was €-0.018.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.


Cynata Therapeutics EV-to-FCF Related Terms

Thank you for viewing the detailed overview of Cynata Therapeutics's EV-to-FCF provided by GuruFocus.com. Please click on the following links to see related term pages.


Cynata Therapeutics Business Description

Traded in Other Exchanges
Address
100 Cubitt Street, Level 3, Cremorne, VIC, AUS, 3121
Cynata Therapeutics Ltd is engaged in the development and commercialization of a proprietary mesenchymal stem cell (MSC) technology for potential human therapeutic use, which is branded as Cymerus. There are currently three active clinical trials taking place using Cymerus technology which are attempting to treat osteoarthritis, respiratory distress, and diabetic foot ulcers.

Cynata Therapeutics Headlines

No Headlines